THTiantian Han

Tiantian Han

*This is an algorithmically generated author record based on publicly available information.

Research Subjects

Research Interests


Tiantian Han has a total of 7 co-authors. Here are the top co-authors by number of shared publications:

  • Didi Guo

    The Medical Department, Jiangsu Simcere Diagnostics Co., Ltd., Nanjing Simcere Medical Laboratory Science Co., Ltd., The State Key Laboratory of Neurology and Oncology Drug Development, Nanjing, Jiangsu, China

    1 shared publication
  • Gaoxin Jin

    Department of Gastrointestinal Surgery, The People's Hospital of Jimo.Qingdao, Qingdao, Shandong, China

    1 shared publication
  • Ningning Luo

    The Medical Department, Jiangsu Simcere Diagnostics Co., Ltd., Nanjing Simcere Medical Laboratory Science Co., Ltd., The State Key Laboratory of Neurology and Oncology Drug Development, Nanjing, Jiangsu, China

    1 shared publication
  • Shisen Li

    Department of Digestive Surgery, Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi'an, Shanxi, China

    1 shared publication
  • Xiangyu Yin

    Department of Biological Sciences, Xi'an Jiaotong-Liverpool University, Suzhou, China

    1 shared publication
  • Xing Zhang

    State Key Laboratory of Neurology and Oncology Drug Development, Jiangsu Simcere Diagnostics Co., Ltd., Nanjing Simcere Medical Laboratory Science Co., Ltd., Nanjing, China.

    1 shared publication

Latest Publications

  • Open Access

    Clinical and genomic features of Lynch syndrome differ by tumor site and disease spectrum

    by Shisen Li, Ningning Luo, Gaoxin Jin, Tiantian Han, Xiangyu Yin, Didi Guo, Xing Zhang, Zhaobang Tan

    Lynch Syndrome (LS) carriers occasionally develop central nervous system (CNS) malignancies or tumors in organs not traditionally linked to the syndrome. These tumors are poorly characterized in the literature, and there is no sufficient consensus on guidelines and management recommendations for these tumors. Here we study LS from the tumor perspective and profile 238 pan-cancer specimens from 228 genetically confirmed LS carriers. Tumors are stratified into CNS LS-related, non-CNS LS-related, and non-CNS LS-unrelated groups according to anatomic site and established LS tumor spectrum. Comparative analyses against TCGA reveal significant alterations in LS incidence within endometrial and hepatic cancers. Across the three groups, we reveal marked heterogeneity in germline pathogenic-variant distribution, age at diagnosis, somatic mutation landscapes, tumor mutational burden, and microsatellite-instability status. This site- and spectrum-based stratification of a large, pan-cancer LS cohort underscores the heterogeneity of the LS and provides a data-driven foundation for refining future disease management strategies.